title: Low-dose histidine-tryptophan-ketoglutarate solution for myocardial protection.
abstract: The effect of histidine-tryptophan-ketoglutarate (HTK) solution for myocardial protection has been shown in experimental and clinical studies using long ischemic times and high dosages. In our study we compared myocardial protection in isolated coronary bypass with a short period of ischemia using low dosage HTK and cold crystalloid cardioplegia. Each group contained 21 coronary artery disease patients. Cardioplegic solutions were administered antegrade in 10 to 15 mL/kg in one shot. This dosage of HTK was lower than that mentioned in the literature. We measured malondialdehyde, lactate, creatine kinase, creatine kinase-MB, and troponin-I levels. Aortic clamping time in the HTK group 33.9 +/- 8.2 minutes, versus 36.2 +/- 11.3 minutes in the crystalloid cardioplegia group (P > .05). Levels of creatine kinase and malondialdehyde were lower in HTK group at 24 hours and 2 minutes, respectively. Lactate levels were lower in the crystalloid cardioplegia group at 2 minutes in the coronary sinus serum sample, but there were no statistically differences among ischemic serum markers in both groups. Only intervals between aortic clamping and cardiac arrest were statistically meaningful (HTK 63.3 +/- 14.7 seconds versus crystalloid cardioplegia 53.6 +/- 15.6 seconds, P = .044). Our study shows that use of low-dose HTK for short clamping time operations is as successful for myocardial protection as crystalloid cardioplegia. Longer times for fibrillation can be explained with the low levels of potassium in HTK solution, but this length did not cause a biochemical or clinical difference.
authors.affiliation: Başkent University, Faculty of Medicine, Department of Cardiovascular Surgery, Ankara, Turkey. barslan26@yahoo.com
authors.forename: A
authors.initials: A
authors.lastname: Arslan
authors.forename: A
authors.initials: A
authors.lastname: Sezgin
authors.forename: B
authors.initials: B
authors.lastname: Gultekin
authors.forename: S
authors.initials: S
authors.lastname: Ozkan
authors.forename: T
authors.initials: T
authors.lastname: Akay
authors.forename: E
authors.initials: E
authors.lastname: Uguz
authors.forename: A
authors.initials: A
authors.lastname: Tasdelen
authors.forename: S
authors.initials: S
authors.lastname: Aslamaci
mesh_terms: D000328:Adult; D000368:Aged; D002314:Cardioplegic Solutions; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000601:surgery*; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D005947:Glucose / Q000627:therapeutic use; D006324:Heart Arrest, Induced; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008353:Mannitol / Q000627:therapeutic use; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000517:prevention & control; D011189:Potassium Chloride / Q000627:therapeutic use; D011343:Procaine / Q000627:therapeutic use; D011446:Prospective Studies; D019210:Troponin I / Q000097:blood
chemical_list: C039984:Bretschneider cardioplegic solution; D002314:Cardioplegic Solutions; D019210:Troponin I; D008353:Mannitol; D008315:Malondialdehyde; D011343:Procaine; D011189:Potassium Chloride; D003402:Creatine Kinase; D005947:Glucose